MedPath

A randomised, open-label, two-way crossover study comparing the pharmacokineticsof a solid dosage form and a solution of PN-943 in healthy volunteers

Phase 1
Completed
Conditions
lcerative Colitis
Ulcerative Colitis
Oral and Gastrointestinal - Inflammatory bowel disease
Registration Number
ACTRN12619001444178
Lead Sponsor
Protagonist Pty Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
10
Inclusion Criteria

Normal healthy volunteers 18-55 years
Good general health,
BMI 18-30kg/m2
Non-smokers
Lab values within normal range. Willing to consume standard meal provided (Standard meal will be as advised by the clinic and principal investigator).
Ability and willingness to attend visits to the site and provide written informed consent prior to entry into the study.

Exclusion Criteria

History of significant abnormalities or diseases
Clinical significant lab or ECG abnormalities
History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular,
haematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
History of neoplastic disease
Mentally or legally incapacitated
History of severe allergic or anaphylactic reactions
History of substance abuse, severe allergic or anaphylactic reactions. Regular Alcohol consumption (>21units per week).
Clinically significant lab abnormality or ECG
Inability to comply with the requirements of the study protocol

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath